title: DNA-48HRS

description: Nothing in line.

source_name: tibialis cranialis muscle, exercised 48 hrs after DNA was injected

treatment_protocol:
Plasmid injection:
Five micrograms of the plasmid phGFP-S65T, encoding the green fluorescent protein (GFP), plasmid was dissolved in 20 μl PBS and injected intramuscularly along the fibres into the tibialis cranialis muscle of anaesthetised C57Bl/6 mice using an insulin syringe.
The muscle was exercised 48 hrs after DNA was injected


title: CONTROL_1

status: Public on Jul 05 2007

type: RNA

city: Hellerup

first: John

middle: R.

last: Zibert

address: Niels Andersens Vej 65, KA-1502

department: Dep. of Dermatology

country: Denmark

institute: Copenhagen University Hospital Gentofte

description: Nothing in line.

hyb_protocol: The biotinlabelled antisense cRNA was fragmentated at 94°C for 35 min in fragmentation buffer (40 mM Tris, 30 mM MgOAc,10 mM KOAc), the labelled cRNA were hybridised for 16 hrs to Affymetrix MOE 430 2.0 arrays (Affymetrix, Santa Clara, CA, USA).The arrays were washed and stained with phycoerythrin conjugated streptavidin using the Affymetrix Fluidics Station® 400.

scan_protocol: The arrays were scanned in the Affymetrix GeneArray® scanner to generate fluorescent images, as described in the Affymetrix GeneChip protocol.

data_processing:
The cel image files (Affymetrix) were imported, pre-processed and analysed in DNA-Chip Analyser 2006 (http://www.dchip.org). The array files were normalised using the non-linear invariant set normalisation
method, choosing array (DNA-EP-48HRS) as baseline. Normalisation curves were visually inspected and none of the arrays were critical. In order to interpret the probe signal, model-based gene expression indexes
(MBEI) gene expression modelling was calculated using the PM/MM perfect match/ miss match) method. During the analysis array outliers were detected. None of the arrays exceeded 1.4% of array outliers
and the probe presence call was between 36.6% and 50.3%.

label: biotin

molecule: polyA RNA

organism: Mus musculus

source_name: tibialis cranialis muscle, exercised, control 1

label_protocol: 5 μg aRNA was used to synthesize double stranded cDNA using Superscript® Choice System (Invitrogen, Denmark) with an oligo(dT) primer containing a T7 RNA polymerase promoter (GenSet, Evry, France). The cDNA was used as template for an IVT reaction to generate biotinlabelled antisense cRNA (BioArrayTM High Yield RNA Transcript Labelling Kit; Enzo Diagnostics, Farmingdale, NY, USA).

growth_protocol: Six to eight weeks old female C57Black/C mice (average weight 22 g, Taconic, Denmark) were kept under pathogen-free conditions at 22 °C in a 14/10 hrs light/dark cycle with food and water ad libitum. All animal experiments were conducted in accordance with the recommendations of the European Convention for the Protection of Vertebrate Animals used for Experimentation and after permission from the Danish Animal Welfare Committee.

extract_protocol: Four hrs, 48 hrs and 3 weeks after treatment the mice were euthanized and the muscles were removed and placed in 1 ml solution D (guandinium thiocyanat, sodium citrate, sarcosyl and mercaptoethanol) on ice. Muscle extracts were prepared by homogenising the muscles with a rotor-stator homogeniser, and RNA were extracted using the Chomczynski and Sacchi method and digested with DNase. Due to low yield of total RNA, mRNA were amplified yielding antisense RNA (aRNA) using the MessageAMP II aRNA kit (Ambion, Europe).

treatment_protocol: A negative control muscle. No treatment at all.

tag: Strain

value: C57Bl/6, gender:female, 8 weeks old.


title: DNA-EP-4HRS_2

description: Nothing in line.

label: Biotin

source_name: tibialis cranialis muscle, exercised 4 hrs after plasmid DNA and in vivo electro gene transfer. Replicate two.

treatment_protocol:
Plasmid DNA and in vivo Electro gene transfer:
Five micrograms of the plasmid phGFP-S65T, encoding the green fluorescent protein (GFP), plasmid was dissolved in 20 μl PBS and injected intramuscularly along the fibres into the tibialis cranialis muscle of anaesthetised C57Bl/6 mice using an insulin syringe. Plate electrodes with 4-mm gap were fitted around the hind legs and an electric field was applied. The muscle was pulsed with a combination of a high voltage pulse (100 μsec, 1000V/cm) followed by a long low voltage pulse (400 ms, 100V/cm) with 1s lag between the pulses.
The tibialis cranialis muscle, exercised 4 hrs after plasmid DNA and in vivo electro gene transfer.


title: CONTROL_2

description: Nothing in line.

source_name: tibialis cranialis muscle, exercised, control 2


title: DT_1

status: Public on Jul 04 2007

city: Edinburgh

first: GUDMAP

last: Developers

address: Crewe Road

country: United Kingdom

institute: IGMM MRC Human Genetics Unit

description:
>> Amplification protocol <<
Target Amplified manufacturer/kit: TargetAmp 2-Round Aminoallyl-aRNA Amplification Kit 1.0 (EPICENTRE Biotechnologies)
Target Amplified protocol: Potter protocols
Rounds of amplification: 2
URL: http://gudmap.hgu.mrc.ac.uk/gudmap/pages/mic_submission.html?id=GUDMAP:8104

hyb_protocol: Affymetrix standard protocol Amount labeled  target hybridization to array: 5ug

scan_protocol: Affymetrix standard protocol

data_processing: Analysis method: Affymetrix GCOS and Gene Spring and Avadis programs GCOS Tgt value: 1500

molecule: total RNA

source_name: anlage of loop of Henle

extract_protocol: Potter protocol: 'RNA purification'

treatment_protocol:
pool size: approx 50 sections from 5 kidneys
Pooled sample: Yes
Dissection Method: Laser capture microdissection
CD-1 mice are time-mated.  Pregnant CD-1 mice are euthanized by standard carbon dioxide asphyxiation.  All fetuses are killed by decapitation with a scalpel.  Fetal kidneys are dissected from fetuses placed in OCT in a mold, frozen in liquid nitrogen and stored at -80°C. Blocks are sectioned, stained and used for laser capture micro-dissection.

tag: gene reported

value: wild-type

tag: strain

tag: Sex

value: Unknown

tag: developmental stage

tag: theiler stage

tag: somite count

tag: developmental landmark


title: DT_3

description:
>> Amplification protocol <<
Target Amplified manufacturer/kit: TargetAmp 2-Round Aminoallyl-aRNA Amplification Kit 1.0 (EPICENTRE Biotechnologies)
Target Amplified protocol: Potter protocols
Rounds of amplification: 2
URL: http://gudmap.hgu.mrc.ac.uk/gudmap/pages/mic_submission.html?id=GUDMAP:8106


title: DEX4_6H

city: London

first: Claudine

last: James

email: claudinegj@hotmail.com, fbeier@uwo.ca

state: Ontario

address: 1151 Richmond Street, Suite 2

department: Physiology and Pharmacology

country: Canada

institute: University of Western Ontario

description: -6 HR TIME POINT

hyb_protocol: According to standard protocols used in London Regional Genomics Centre. Ontario, Canada

data_processing:
Microarray data were pre-processed using the GC-RMA algorithm in Genespring GX* Expression values were further filtered by retaining only those  probe sets with expression values of at least 50 in at least 25% of all conditions,
thus generating a list of 22 091 probe sets. To assess differential gene expression between treatments at both the 6 and 24 hr time points, a Welch ANOVA test with a p-value cut-off of 0.01 and a 5% false discovery rate (FDR)
reduced the data to 1158 probe sets. Subsequent 1.5-, 5- and 10-fold change filters produced lists of 162, 21 and 7 probe sets for the 6 hr time point and 399, 53 and 19 probe sets for the 24 hr time point, respectively.
The same data set was normalized in parallel using Robust Multichip Analysis using RMAEXPRESS software v.0.4.1 developed by B. Bolstad, University of California, Berkeley. Background adjustment and quantile
normalization parameters were selected for data processing. Logarithmically transformed expression values were used to implement Gene Set Enrichment Analysis (GSEA).

label: ONE COLOUR: SAPE

source_name: DEX-treated embryonic primary chondrocyte cultures, incubated for 6hr

label_protocol: Completed according to the London Regional Genomics Centre (LRGC): http://www.lrgc.ca/

growth_protocol: Tibiae, femurs and humeri were isolated from E15.5 mouse embryos and placed in alpha-MEM media (Invitrogen) containing 0.2% Bovine Serum Albumin (BSA), 1 mM beta-glycerophosphate, 0.05 mg/ml ascorbic acid and penicillin/streptomycin incubated at 37°C in a humidified 5% CO2 incubator overnight. The following morning media was removed and the bones placed in 4 ml of 0.25% trypsin-EDTA (Invitrogen) for 15 min at 37oC. Trypsin was subsequently replaced with 1 mg/ml collagenase P (Roche) in DMEM / 10% fetal bovine serum (Invitrogen), and cells were incubated at 37°C with rotation at 100 rpm for 90 min. Following digestion, the cell suspension was centrifuged for 5 min at 1000 rpm, and the collagenase containing supernatant was decanted. Chondrocytes were resuspended in media containing 2:3 DMEM:F12, 10% fetal bovine serum, 0.5 mM L-glutamine, and penicillin/streptomycin (25 units/ml). Cells were seeded in 6-well NUNC plates at a density of 2.5X104 cells per ml and incubated overnight.

extract_protocol: Qiagen RNeasy extraction

treatment_protocol: Primary monolayer chondrocytes were treated with 10-7 M dexamethasone (DEX) or the DMSO control (vehicle) diluted in fresh media supplemented with 0.25 mM ascorbic acid (Sigma) and 1 mM beta-glycerophosphate (Sigma) and incubated for up to 24 hrs


title: DT_2

description:
>> Amplification protocol <<
Target Amplified manufacturer/kit: TargetAmp 2-Round Aminoallyl-aRNA Amplification Kit 1.0 (EPICENTRE Biotechnologies)
Target Amplified protocol: Potter protocols
Rounds of amplification: 2
URL: http://gudmap.hgu.mrc.ac.uk/gudmap/pages/mic_submission.html?id=GUDMAP:8105


title: DEX1_6HR

description: -6 hr time point

scan_protocol: According to standard protocols used in London Regional Genomics Centre. Ontario, Canada

data_processing:
Microarray data were pre-processed using the GC-RMA algorithm in Genespring GX* Expression values were further filtered by retaining only those  probe sets with expression values of at least 50 in at least 25% of all conditions,
thus generating a list of 22 091 probe sets. To assess differential gene expression between treatments at both the 6 and 24 hr time points, a Welch ANOVA test with a p-value cut-off of 0.01 and a 5% false discovery rate (FDR)
reduced the data to 1158 probe sets. Subsequent 1.5-, 5- and 10-fold change filters produced lists of 162, 21 and 7 probe sets for the 6 hr time point and 399, 53 and 19 probe sets for the 24 hr time point, respectively.
The same data set was normalized in parallel using Robust Multichip Analysis using RMAEXPRESS software v.0.4.1 developed by B. Bolstad, University of California, Berkeley. Background adjustment and quantile
normalization parameters were selected for data processing. Logarithmically transformed expression values were used to implement Gene Set Enrichment Analysis (GSEA). DESCRIPTION

tag: DEX-treated embryonic primary chondrocyte cultures, incubated for 6hr


title: DMSO4_6H

description: -6 hr time point

source_name: DMSO-treated embryonic primary chondrocyte cultures, incubated for 6hr


title: DEX2_6H

description: - 6hr time point

source_name: DEX-treated embryonic primary chondrocyte cultures, incubated for 6hr.


title: CC_3

description:
>> Amplification protocol <<
Target Amplified manufacturer/kit: TargetAmp 2-Round Aminoallyl-aRNA Amplification Kit 1.0 (EPICENTRE Biotechnologies)
Target Amplified protocol: Potter protocols
Rounds of amplification: 2
URL: http://gudmap.hgu.mrc.ac.uk/gudmap/pages/mic_submission.html?id=GUDMAP:8103

source_name: Cortical Collecting Duct


title: DMSO2_24H

description: -vehicle treatment

data_processing:
Microarray data were pre-processed using the GC-RMA algorithm in Genespring GX* Expression values were further filtered by retaining only those  probe sets with expression values of at least 50 in at least 25% of all conditions, thus generating a list of 22 091 probe sets. To assess differential gene expression between treatments at both the 6 and 24 hr time points, a Welch ANOVA test with a p-value cut-off of 0.01 and a 5% false discovery rate (FDR) reduced the data to 1158 probe sets. Subsequent 1.5-, 5- and 10-fold change filters produced lists of 162, 21 and 7 probe sets for the 6 hr time point and 399, 53 and 19 probe sets for the 24 hr time point, respectively.
The same data set was normalized in parallel using Robust Multichip Analysis using RMAEXPRESS software v.0.4.1 developed by B. Bolstad, University of California, Berkeley. Background adjustment and quantile normalization parameters were selected for data processing. Logarithmically transformed expression values were used to implement Gene Set Enrichment Analysis (GSEA).

label: ONE COLOUR ARRAY-SAPE

source_name: DMSO-treated embryonic primary chondrocyte cultures, incubated for 24hr.


title: DEX4_24H

description: -24 hr time point

data_processing:
Microarray data were pre-processed using the GC-RMA algorithm in Genespring GX* Expression values were further filtered by retaining only those  probe sets with expression values of at least 50 in at least 25% of all conditions,
thus generating a list of 22 091 probe sets. To assess differential gene expression between treatments at both the 6 and 24 hr time points, a Welch ANOVA test with a p-value cut-off of 0.01 and a 5% false discovery rate (FDR)
reduced the data to 1158 probe sets. Subsequent 1.5-, 5- and 10-fold change filters produced lists of 162, 21 and 7 probe sets for the 6 hr time point and 399, 53 and 19 probe sets for the 24 hr time point, respectively.
The same data set was normalized in parallel using Robust Multichip Analysis using RMAEXPRESS software v.0.4.1 developed by B. Bolstad, University of California, Berkeley. Background adjustment and quantile
 normalization parameters were selected for data processing. Logarithmically transformed expression values were used to implement Gene Set Enrichment Analysis (GSEA).

source_name: DEX-treated embryonic primary chondrocyte cultures, incubated for 24hr


title: DEX2_24H

description: 24 hr time point

source_name: DEX-treated embryonic primary chondrocyte cultures, incubated for 24hr.

tag: Timed-pregnant CD1 mice were purchased from Charles River Laboratories at embryonic day E15.5 mice (E15.5). Dexamethasone was obtained from Calbiochem and reconstituted in Dimethyl sulfoxide (DMSO, vehicle).


title: DMSO2_6H

description: - 6 hr time point

source_name: DMSO-treated embryonic primary chondrocyte cultures, incubated for 6hr.

tag: Mouse supplier

value: Charles River.  Cultures were completed in Frank Beiers laborartory by Veronica Ulici and Claudine James


title: DEX1_24H

description: -24 hour time point

tag: DEX-treated embryonic primary chondrocyte cultures, incubated for 24hr


title: Lymphoblastoid Cell Line for Individual 8213.3 log phase

status: Public on Jul 01 2007

city: Ann Arbor

first: Goncalo

last: Abecasis

state: MI

address: 1420 Washington Heights

country: USA

institute: University of Michigan

description: no additional

hyb_protocol: Procedure used standard Affymetrix labelling protocol.

data_processing: RMA Express

organism: Homo sapiens

growth_protocol: Previously transformed cryo-preserved EBV cell lines were grown as 500 ml roller cultures. Once log phase had been obtained, cells were pelleted, media discarded and a mixture of RLT buffer and β-mercaptoethanol added.  Pellets were vortexed to ensure thorough re-suspension after which they were frozen at -70oC and kept at -80oC.

extract_protocol: RNA was extracted in using the RNeasy Maxi Kit.

tag: ped

tag: id

tag: fatid

tag: motid

tag: sex

tag: country

value: UK

tag: DDAST

value: CASE

value: CC

value: TT

value: GG

value: AA

value: GT

value: TC

value: AG

value: GA

value: AC

value: CT


title: DMSO1_24H

description: -24 hr time point

source_name: DMSO-treated embryonic primary chondrocyte cultures, incubated for 24hr


title: Lymphoblastoid Cell Line for Individual 8214.4 log phase

description: no additional

scan_protocol: Procedure used standard Affymetrix labelling protocol.


title: DMSO4_24H

description: -24 hr time point

data_processing:
Microarray data were pre-processed using the GC-RMA algorithm in Genespring GX* Expression values were further filtered by retaining only those  probe sets with expression values of at least 50 in at least 25% of all conditions, thus generating a list of 22 091 probe sets. To assess differential gene expression between treatments at both the 6 and 24 hr time points, a Welch ANOVA test with a p-value cut-off of 0.01 and a 5% false discovery rate (FDR)
reduced the data to 1158 probe sets. Subsequent 1.5-, 5- and 10-fold change filters produced lists of 162, 21 and 7 probe sets for the 6 hr time point and 399, 53 and 19 probe sets for the 24 hr time point, respectively.
The same data set was normalized in parallel using Robust Multichip Analysis using RMAEXPRESS software v.0.4.1 developed by B. Bolstad, University of California, Berkeley. Background adjustment and quantile
 normalization parameters were selected for data processing. Logarithmically transformed expression values were used to implement Gene Set Enrichment Analysis (GSEA).

tag: DMSO-treated embryonic primary chondrocyte cultures, incubated for 24hr


title: DMSO1_6H

description: -6 hr time point

tag: DMSO-treated embryonic primary chondrocyte cultures, incubated for 6hr.


title: Hippocampus Fluoxetine group 2

city: Jupiter

first: Mathew

middle: T

last: Pletcher

state: FL

address: 5353 Parkside Dr

institute: Scripps Florida

description: All protocols from Affymetrix GeneChip Expression Analysis technical manual

hyb_protocol: According to Affymetrix Standard Protocols

data_processing: GCRMA normalization with Spotfire

source_name: DBA/2J hippocampus-Fluoxetine

extract_protocol: TRIzol isolation followed by QIAgen clean-up kit

treatment_protocol: Fluoxetine dissolved in drinking water to provide a dose of 18 mg/kg/day for 21 days

tag: Strain

value: DBA/2J Sex:Male Age:8-10 weeks Treatment:Fluoxetine


title: Hippocampus Control group 1

scan_protocol: According to Affymetrix Standard Protocols

source_name: DBA/2J hippocampus-Control

tag: Sex

value: Male

tag: Age

value: 8-10 weeks

tag: Treatment

value: Control


title: Hippocampus Fluoxetine Group 1

label_protocol: According to Affymetrix Standard Protocols


title: Hippocampus Control group 2

treatment_protocol: Control

value: DBA/2J Sex:Male Age:8-10 weeks Treatment:Control


title: Lymphoblastoid Cell Line for Individual 8213.4 log phase

description: no additional

label_protocol: Procedure used standard Affymetrix labelling protocol.

value: UK

value: CONTROL


title: Lymphoblastoid Cell Line for Individual 8213.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8211.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8209.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8206.3 log phase

description: no additional

value: CASE


title: Lymphoblastoid Cell Line for Individual 8210.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8209.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8211.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8210.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8207.3 log phase

description: no additional

value: TT

value: CC

value: TG


title: Lymphoblastoid Cell Line for Individual 8203.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8207.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8206.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8208.4 log phase

description: no additional

value: CA

value: GG

value: AA

value: GT


title: Lymphoblastoid Cell Line for Individual 8203.4 log phase

description: no additional

value: TC

value: AC

value: AG

value: GA


title: Lymphoblastoid Cell Line for Individual 8204.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8202.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8204.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8201.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8205.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8201.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8205.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8201.6 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8200.3 log phase

description: no additional

value: CT


title: Lymphoblastoid Cell Line for Individual 8201.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8202.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8200.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8199.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8199.4 log phase

description: no additional


title: SN:1022907;Fetal Cartilage, biological rep2 validation

status: Public on Jul 06 2007

city: Los Angeles

first: Vincent

middle: Anthony

last: Funari

state: CA

address: 8700 Beverly Drive

department: Medical Genetics

institute: Cedars Sinai

description: Normal human fetal cartilage from 18-22 weeks.

hyb_protocol: Following fragmentation, 10 microg of cRNA were hybridized for 16 hr at 45C on GeneChip U133 plus 2.0 Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.

scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.

data_processing: The data were analyzed using R 2.2.1 and RMA as normalization method with PM model.

source_name: RNA isolated from Fetal Cartilage 18-22 weeks - rep2 validation

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 microg total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).

extract_protocol: Trizol extraction of total RNA was performed according to the manufacturer's instructions.

treatment_protocol: Distal fetal cartilage from femur of Homo sapiens at 18-22 weeks was dissected from non cartilage tissue using a dissecting scope. RNA was isolated from Cartilage using the Trizol solution (GibcoBRL).

tag: Normal Fetal Cartilage from Distal Femur


title: Lymphoblastoid Cell Line for Individual 8199.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8197.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8198.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8198.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8196.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8196.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8196.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8190.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8195.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8193.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8193.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8188.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8197.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8193.6 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8187.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8184.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8191.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8194.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8189.4 log phase

description: no additional


title: DNA-3W

description: Nothing in line.

source_name: tibialis cranialis muscle, exercised 3 weeks after DNA injected

treatment_protocol:
Plasmid injection:
Five micrograms of the plasmid phGFP-S65T, encoding the green fluorescent protein (GFP), plasmid was dissolved in 20 μl PBS and injected intramuscularly along the fibres into the tibialis cranialis muscle of anaesthetised C57Bl/6 mice using an insulin syringe.
The muscle was exercised 3 weeks after DNA was injected

value: C57Bl/6, gender:female, 8 weeks old.


title: Lymphoblastoid Cell Line for Individual 8192.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8188.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8189.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8185.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8186.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8191.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8190.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8192.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8183.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8185.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8184.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8183.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8182.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8181.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8178.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8179.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8182.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8177.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8177.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8180.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8178.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8174.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8177.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8180.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8175.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8175.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8174.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8174.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8176.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8173.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8176.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8179.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8171.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8172.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8169.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8172.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8171.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8175.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8170.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8172.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8169.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8173.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8169.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8170.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8165.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8167.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8166.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8166.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8164.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8165.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8165.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8167.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8168.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8168.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8163.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8164.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8162.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8161.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8163.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8162.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8163.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8160.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8159.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8158.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8158.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8157.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8159.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8156.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8155.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8152.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8153.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8150.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8157.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8151.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8155.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8161.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8154.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8156.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8153.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8156.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8152.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8154.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8148.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8151.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8148.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8149.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8147.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8148.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8145.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8150.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8146.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8146.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8145.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8147.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8142.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8143.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8144.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8143.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8141.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8139.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8136.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8140.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8135.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8137.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8137.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8138.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8141.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8139.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8138.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8136.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8135.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8133.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8136.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8131.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8128.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8135.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8132.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8130.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8134.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8129.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8131.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8130.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8132.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8133.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8127.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8127.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8129.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8124.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8125.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8123.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8128.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8125.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8125.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8124.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8122.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8123.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8126.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8124.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8126.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8127.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8120.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8118.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8121.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8115.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8122.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8121.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8119.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8118.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8118.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8115.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8115.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8114.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8116.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8114.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8118.6 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8117.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8116.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8120.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8117.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8113.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8111.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8110.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8111.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8113.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8109.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8113.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8111.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8108.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8110.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8109.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8108.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8107.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8112.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8112.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8106.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8105.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8104.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8105.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8107.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8104.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8102.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8101.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8101.6 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8100.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8100.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8100.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8101.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8103.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8103.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8098.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8097.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8096.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8094.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8094.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8098.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8108.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8099.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8093.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8101.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8099.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8093.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8091.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8091.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8089.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8090.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8096.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8087.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8092.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8089.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8084.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8087.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8092.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8085.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8088.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8083.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8090.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8084.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8083.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8080.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8080.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8078.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8076.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8075.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8075.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8080.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8081.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8081.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8076.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8079.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8079.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8073.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8067.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8069.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8075.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8066.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8065.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8073.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8070.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8068.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8073.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8070.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8072.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8069.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8067.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8064.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8064.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8064.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8063.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8063.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8062.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8072.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8061.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8062.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8061.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8060.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8060.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8054.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8054.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8066.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8052.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8057.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8055.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8060.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8052.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8055.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8058.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8059.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8059.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8058.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8053.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8057.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8065.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8054.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8050.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8050.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8047.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8047.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8046.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8051.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8048.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8049.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8049.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8046.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8051.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8045.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8041.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8043.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8042.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8041.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8044.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8037.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8037.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8038.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8042.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8097.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8040.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8044.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8039.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8040.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8038.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8043.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8039.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8036.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8028.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8036.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8032.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8034.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8030.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8028.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8020.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8034.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8022.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8021.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8033.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8025.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8033.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8027.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8026.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8017.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8026.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8017.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8023.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8019.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8016.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8020.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8019.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8022.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8015.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8021.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8030.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8016.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8014.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8013.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8008.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8012.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8015.5 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8008.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8007.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8010.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8006.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8009.3 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8007.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8013.4 log phase

description: no additional


title: Lymphoblastoid Cell Line for Individual 8010.4 log phase

description: no additional


title: striatum_wt_3m_436

city: Bethesda

first: Alexandre

last: Kuhn

state: MD

address: 35 Convent Dr

department: NIA

institute: NIH

description: Affymetrix GeneChip® Mouse Genome 430 2.0 Array

hyb_protocol: Affymetrix Eukaryotic Target Hybridization protocol for 100 Format midi arrays (GeneChip® Expression Analysis Technical Manual 701021 Rev. 5)

scan_protocol: Affymetrix® GeneChip® Scanner 3000 with GCOS software according to manufactuer's protocol (GeneChip® Expression Analysis Technical Manual 701021 Rev. 5)

data_processing: Probe set summarization and normalization was performed by robust multi-array averaging (RMA, including background subtraction, summarization by median polish and quantile normalization) using the R/Bioconductor package affy.

source_name: Striatum (brain)

label_protocol: Affymetrix GeneChip® IVT Labeling Kit, according to manufactuer's protocol (GeneChip® Expression Analysis Technical Manual 701021 Rev. 5)

extract_protocol: TRIzol (Invitrogen) followed by RNeasy column cleanup (Qiagen) using the manufacturers’ protocols

value: C57BL/6; Gender:male; Age:103 days; Tissue:striatum (brain); Mouse model:wild-type


title: Lymphoblastoid Cell Line for Individual 8003.5 log phase

description: no additional

value: UK


title: striatum_Q92_3m_440

value: C57BL/6; Gender:female; Age:103 days; Tissue:striatum (brain); Mouse model:HdhQ92/Q92 knock-in mice carrying 92 CAG repeats derived from exon 1 of human HD gene knocked in to of the endogenous mouse gene (Wheeler, V.C. et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115-122 (1999))


title: striatum_wt_3m_467

value: C57BL/6; Gender:male; Age:100 days; Tissue:striatum (brain); Mouse model:wild-type


title: Lymphoblastoid Cell Line for Individual 8004.4 log phase

description: no additional

value: CONTROL

value: TT


title: striatum_Q92_3m_439


title: Lymphoblastoid Cell Line for Individual 8005.4 log phase

description: no additional

value: CASE

value: CC


title: striatum_wt_18m_17

value: C57BL/6; Gender:female; Age:596 days; Tissue:striatum (brain); Mouse model:wild-type


title: Lymphoblastoid Cell Line for Individual 8004.3 log phase

description: no additional

value: TG

value: GG

value: CA

value: AA


title: striatum_Q92_18m_66

value: C57BL/6; Gender:female; Age:574 days; Tissue:striatum (brain); Mouse model:HdhQ92/Q92 knock-in mice carrying 92 CAG repeats derived from exon 1 of human HD gene knocked in to of the endogenous mouse gene (Wheeler, V.C. et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115-122 (1999))


title: Lymphoblastoid Cell Line for Individual 8006.4 log phase

description: no additional

value: TC

value: AG

value: AC

value: GA

value: GT


title: striatum_Q92_3m_466

value: C57BL/6; Gender:male; Age:100 days; Tissue:striatum (brain); Mouse model:HdhQ92/Q92 knock-in mice carrying 92 CAG repeats derived from exon 1 of human HD gene knocked in to of the endogenous mouse gene (Wheeler, V.C. et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115-122 (1999))


title: Lymphoblastoid Cell Line for Individual 8003.4 log phase

description: no additional

value: UK


title: Lymphoblastoid Cell Line for Individual 8003.6 log phase

description: no additional

value: CT


title: striatum_Q92_18m_25

value: C57BL/6; Gender:female; Age:567 days; Tissue:striatum (brain); Mouse model:HdhQ92/Q92 knock-in mice carrying 92 CAG repeats derived from exon 1 of human HD gene knocked in to of the endogenous mouse gene (Wheeler, V.C. et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115-122 (1999))


title: striatum_wt_3m_438

value: C57BL/6; Gender:female; Age:103 days; Tissue:striatum (brain); Mouse model:wild-type


title: Lymphoblastoid Cell Line for Individual 8045.4 log phase

description: no additional

value: CONTROL

value: CC

value: TT


title: Lymphoblastoid Cell Line for Individual 8002.4 log phase

description: no additional


title: striatum_wt_18m_12

value: C57BL/6; Gender:male; Age:596 days; Tissue:striatum (brain); Mouse model:wild-type


title: placenta-0649-uninflamed-past-rep1

city: Seattle

first: Atis

last: Muehlenbachs

state: WA

address: 307 Westlake Ave N

institute: Seattle Biomedical Research Institute

description: Gene expression data from a placenta without malaria, but with histological evidence of a past infection

hyb_protocol: Following fragmentation, 15 ug of cRNA were hybridized for 16 hr. The chips were then washed and stained with streptavidin-phycoerythrin using the Affymetrix GeneChip System 400.

scan_protocol: Chips were scanned using the GeneChip Scanner.

data_processing: Affymetrix .CEL files were normalized using GC-RMA on Acuity 4.0

source_name: placenta without malaria

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 5 ug total RNA.

extract_protocol: RNA extracted using Qiagen Rneasy kits per manufacturer's protocol

treatment_protocol: Tissue collected fresh at delivery, stored in RNAlater -80 degrees celsius

tag: StudyID

tag: Inflammation

value: No

tag: ChronicPM

value: control

tag: PM status

value: uninfected (past)

tag: %parasitemia

tag: InfantSex

value: Female

tag: MaternalAge

tag: Birthweight(kg)


title: placenta-0540-inflamed-past-rep1

description: Gene expression data from a placenta without malaria, but with histological evidence of a past infection and inflammatory cells

value: Yes

value: Male


title: Lymphoblastoid Cell Line for Individual 8001.4 log phase

description: no additional

tag: ped

tag: id

tag: fatid

tag: motid

tag: sex

tag: country

value: TC

value: AG

value: AC

value: GG

value: AA

value: GA

value: CA


title: striatum_Q92_18m_11

tag: Strain

value: C57BL/6; Gender:male; Age:596 days; Tissue:striatum (brain); Mouse model:HdhQ92/Q92 knock-in mice carrying 92 CAG repeats derived from exon 1 of human HD gene knocked in to of the endogenous mouse gene (Wheeler, V.C. et al. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115-122 (1999))


title: placenta-0482-uninflamed-past-rep1


title: placenta-0475-uninflamed-past-rep1


title: placenta-0716-inflamed-infected-rep1

description: Gene expression data from a placenta with chronic malaria

source_name: placenta with chronic malaria

tag: PM Status

value: infected


title: IEC2

city: Minato-ku

first: Kazutaka

last: Terahara

address: 4-6-1 Shirokanedai

department: Institute of Medical Science

country: Japan

institute: The University of Tokyo

description: Epithelial cells in duodenal villi of naive BALB/c mice were stained with NKM16-2-4 monoclonal antibody (mAb)-FITC, lectin UEA-1-PE, and anti-CD45 mAb-APC-Cy7. IECs (NKM16-2-4-, UEA-1-, and CD45- cells) were isolated by FACS.

hyb_protocol: The cRNA was hybridized with DNA probes on a GeneChip Mouse Genome 430 2.0 Array (Affymetrix), washed, and fluorescence-labeled in accordance with the standard amplification protocol for eukaryotic targets developed by Affymetrix.

scan_protocol: The arrays were scanned with a GeneChip Scanner 3000 7G (Affymetrix). The fluorescence intensity of each probe was taken to represent the raw expression level and was quantified using GeneChip Operating software (Affymetrix).

data_processing: The fluorescence intensity of each probe was taken to represent the raw expression level and was quantified using GeneChip Operating Software (Affymetrix).

source_name: IEC

label_protocol: Biotinylated cRNA was prepared using a two-cycle target labeling assay in accordance with the protocol of the manufacture (Affymetrix, Santa Clara, CA, USA).

extract_protocol: RNA was isolated with a High Pure RNA Tissue Kit (Roche, Penzberg, Germany) according to the manufacturer’s instructions.

tag: Intestinal epithelial cell (IEC)


title: IEC3


title: placenta-0409-uninflamed-past-rep1

tag: StudyID


title: CT-v-M cell2

description: Epithelial cells in duodenal villi of CT-administered BALB/c mice were stained with NKM16-2-4 monoclonal antibody (mAb)-FITC, lectin UEA-1-PE, and anti-CD45 mAb-APC-Cy7. Induced villous M cells (NKM16-2-4+, UEA-1+, and CD45- cells) were isolated by FACS.

source_name: CT-v-M cell

tag: Cholera toxin-induced villous M cell


title: placenta-0702-uninflamed-infected-rep1

description: Gene expression data from a placenta with acute malaria

source_name: placenta with acute malaria

tag: Inflammation

tag: ChronicPM

value: case


title: placenta-0687-inflamed-infected-rep1

tag: %parasitemia


title: placenta-0545-uninflamed-infected-rep1

tag: InfantSex


title: PP M CELL2

description: Epithelial cells in duodenal Peyer's patches (PP) of naive BALB/c mice were stained with NKM16-2-4 monoclonal antibody (mAb)-FITC, lectin UEA-1-PE, and anti-CD45 mAb-APC-Cy7. PP M cells (NKM16-2-4+, UEA-1+, and CD45- cells) were isolated by FACS.

source_name: PP M CELL

tag: Mouse Peyer's patch M cell


title: rad001 9d, biological rep3

city: boston

first: qing

last: xu

state: MA

address: 44 binney st

department: Medical Oncology

institute: dana farber cancer institute

description: Gene expression data from ventral prostate of wild type FVB mice and FVB-AKT1 mice treated with placebo or rad001 for 12h, 2d, 6d, 9d, and 15d

hyb_protocol: standard procedure carried out at Broad Institute

data_processing: CEL files were normalized with dChip, then expression values were computed and merged and normalized again with dChip.

source_name: ventral prostate of transgenic FVB mice

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 10 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).

growth_protocol: standard mouse diet

treatment_protocol: rad001 for 9d

tag: Genotype

value: transgenic

tag: Age

value: 8-10 weeks


title: CT-v-M cell3


title: CT-v-M cell1


title: placenta-0586-inflamed-infected-rep1

tag: MaternalAge

tag: Birthweight(kg)


title: placenta-0660-inflamed-infected-rep1


title: striatum_wt_18m_9

value: C57BL/6; Gender:female; Age:604 days; Tissue:striatum (brain); Mouse model:wild-type


title: IEC1


title: rad001 9d, biological rep2

scan_protocol: standard procedure carried out at Broad Institute


title: PP M CELL3


title: placenta-0638-inflamed-infected-rep1


title: rad001 9d, biological rep4


title: PP M CELL1


title: rad001 9d, biological rep1


title: placenta-0460-inflamed-infected-rep1


title: placenta-0543-inflamed-infected-rep1


title: rad001 6d, biological rep3

treatment_protocol: rad001 for 6d


title: rad001 6d, biological rep2


title: placenta-0517-uninflamed-uninfected-rep1

description: Gene expression data from a placenta without malaria

value: No

value: control

tag: PM status

value: uninfected


title: rad001 6d, biological rep1


title: placenta-0606-uninflamed-uninfected-rep1

value: Male


title: placenta-0735-uninflamed-uninfected-rep1


title: placebo 6d, biological rep1

treatment_protocol: placebo for 6d


title: placenta-0491-uninflamed-infected-rep1

value: Female


title: placenta-0502-uninflamed-uninfected-rep1


title: placenta-0449-uninflamed-uninfected-rep1


title: bladder_T1GH_pool-3

city: Barcelona

first: Moises

middle: Burset

last: Albareda

state: Barcelona

address: Cartagena, 340-350

department: Molecular biology

country: Spain

institute: Fundacio Puigvert

description: Individual array of a bladder cancer expression experiment.

hyb_protocol: 15 µg of fragmented and labelled cRNA were hybridized according to standard Affymetrix protocol for U133 plus 2.0 array.

scan_protocol: According to standard Affymetrix protocol for U133 plus 2.0 array.

data_processing:
Data was obtained from cel files under R using the RMA algorithm as:
library(affyPLM);
data<-ReadAffy(celfile.path="cel/");
X<-rma(data);
result<-exprs(X);
write.table(result,"rma.raw");

source_name: Tumoral bladder tissues, T1 high grade

extract_protocol:
Tissues were mechanically homogenized in TRIzol reagent.
Total RNA was extracted following TRIzol manufacturer's instructions and subsequently purified according to the "Clean up protocol” of the RNeasy RNA extraction kit (Qiagen, Valencia, TX).
5 µg of pooled total RNA (with equimolar contribution of each sample) were used in a reverse transcription reaction to synthesize cDNA using standard Affymetrix protocols (http://www.affymetrix.com/support/technical/manual/expression_manual.affx)

tag: Tissues extracted using cold cup from transurethral resections.

tag: Immediately frozen and stored at -80ºC until processed.

tag: Pool of 4 individual samples.


title: whole animal, whole head: Shu 50 #3_le1

status: Public on Jun 30 2007

city: Phoenix

first: Winnie

last: Liang

state: AZ

address: 445 N. Fifth Street

institute: Translational Genomics

description:
Mutant, 50 mM treatment, sample #3
Treatment, type=acclimatization

hyb_protocol: standard Affymetrix protocol

scan_protocol: standard Affymetrix protocol

organism: Drosophila melanogaster

source_name: whole animal, whole head

label_protocol: standard Affymetrix protocol

extract_protocol: not supplied


title: whole animal, whole head: Shu 50 #1_le1

description:
Mutant, 50 mM treatment, sample #1
Treatment, type=acclimatization


title: bladder_T2-4_pool-2

source_name: Tumoral bladder tissues, T2, T3 or T4 (high grade)

label_protocol: According to standard Affymetrix protocol for U133 plus 2.0 array.

tag: Pool of 5 individual samples.


title: bladder_T2-4_pool-1


title: bladder_control_pool-2

source_name: Normal bladder tissue

tag: Tissue extracted resecting a bladder area using scissors.

tag: Immediately frozen and store at -80ºC until processed.


title: whole animal, whole head: CS 50 #2_le1

description:
Wild type, 50 mM lithium treatment, sample #1
Treatment, type=acclimatization, description=treated with 50  mM lithium


title: bladder_TaGL_pool-1

source_name: Tumoral bladder tissues, Ta low grade


title: whole animal, whole head: CS 0 #2_le1

description:
Wild type, no treatment, sample #2
Treatment, type=acclimatization


title: whole animal, whole head: Shu 50 #2_le1

description:
Mutant, 50 mM treatment, sample #2
Treatment, type=acclimatization


title: whole animal, whole head: Shu 0 #3_le1

description:
Mutant, no treatment, sample #3
Treatment, type=acclimatization


title: whole animal, whole head: CS 50 #3_le1

description:
Wild type, 50 mM lithium treatment, sample #3
Treatment, type=acclimatization, description=treated with 50  mM lithium


title: bladder_T2-4_pool-3


title: bladder_T1GH_pool-1


title: bladder_control_pool-3


title: whole animal, whole head: Shu 0 #1_le1

description:
Mutant, no treatment, sample #1
Treatment, type=acclimatization


title: bladder_T1GH_pool-2


title: bladder_control_pool-1


title: whole animal, whole head: CS 0 #1_le1

description:
Wild type, no treatment, sample #1
Treatment, type=acclimatization


title: whole animal, whole head: CS 0 #3_le1

description:
Wild type, no treatment, sample #3
Treatment, type=acclimatization


title: whole animal, whole head: Shu 0 #2_le1

description:
Mutant, no treatment, sample #2
Treatment, type=acclimatization


title: bladder_TaGL_pool-2


title: bladder_TaGL_pool-3


title: whole animal, whole head: CS 50 #1_le1


title: HSPH_MIPS_murlungs_430_Particles12

city: Boston

first: Alexey

last: Fedulov

address: 75 Francis St.

department: Brigham and Women's Hospital

institute: Harvard Medical School

description:
Sample # Group OD 260/280 RNA, ug/ul Actb Ct Chip
1 PregPBS 2.0 0.63 13.8 a
2 PregPBS 2.0 0.647 13.3 j
3 PregPBS 2.1 0.612 13.4 l
4 PregPBS 2.0 0.575 13.8 m
6 PregTiO 2.1 0.585 14.3 n
8 PregTiO 2.1 0.458 13.8 o
9 NormPBS 2.0 0.627 13.3 p
11 NormPBS 2.0 0.714 13.4 b
12 NormPBS 2.1 0.462 13.8 c
13 NormTiO 2.0 0.572 15.6 d
14 NormTiO 2.1 0.598 13.1 e
15 NormTiO 2.1 0.682 13.6 f
16 NormTiO 2.1 0.654 13.6 g
17 PregTiO 2.1 0.586 13.7 h
18 PregTiO 2.0 0.833 12.8 i
20 NormPBS 2.0 0.804 12.5 k

hyb_protocol: Hybridization is carried out according the Affymetrix GeneChip® Manual. Twenty micrograms of IVT material is the nominal amount used on the GeneChip® arrays. Affymetrix hybridization ovens are used to incubate the arrays at a constant temperature of 45oC overnight.

scan_protocol: Preparation of microarrays for scanning is carried out with Affymetrix appropriate wash protocols matched to the specific chip type on a Model 450 Fluidics station. Affymetrix GeneChip Operating Software (GCOS) operating system controls the Fluidics station process. Scanning is carried out on a GeneChip® Scanner 3000 7G scanner with autoloader. The Affymetrix GCOS v1.3 operating system controls the Model 3000 7G scanner and data acquisition functions. GCOS maintains the mediated first level data analysis and desktop data management for the entire GeneChip System. Chip library files specific to each array and necessary for scan interpretation are stored on the computer workstation controlling the scanner and are updated regularly as necessary when updates are made available from Affymetrix. Collected research data is stored on the hard drive of the instrument computer, transferred to a mirrored storage disk and to a raid 5 server operating on the Partners Healthcare network and backed up nightly via the Partners Healthcare Systems IT backup utility. All systems are CFR21-11 and HIPPA compliant

data_processing: GCOS/MAS5 and RMA-SAM-ANOVA

source_name: Total lung RNA of pregnant mouse exposed to PBS insufflation

label_protocol: For each experimental sample, RNA quality was assessed by RNA Nano LabChip analysis on an Agilent Bioanalyzer 2100. Concentrations may also be determined using a NanoDrop 1000 spectrophotometer. Under standard conditions processing of RNAs for GeneChip Analysis was in accordance with methods described in the Affymetrix GeneChip Expression Analysis Technical Manual, revision four, as subsequently detailed. Synthesis of cDNA first and second strand is performed using the GeneChip Expression 3’-Amplification Reagents One-Cycle cDNA Synthesis Kit (P/N 900431). Cleanup of the double stranded product is carried according to standard Affymetrix protocols using the Affymetrix GeneChip Cleanup Module (Affymetrix Catalog # 900371). In vitro transcription (IVT) is performed using the GeneChip Expression Amplification Reagents kit- 30 reactions (P/N 900449) and is carried out according to the standard Affymetrix protocols and quantification of the IVT samples is carried out on a Bio-Tek UV Plate Reader.

extract_protocol: Qiagen RNeasy extraction with dual elution

tag: Strain

value: BALB/c

tag: Gender

value: female

tag: Gestation

value: 14 days

tag: Exposure

value: PBS insufflation control


title: HSPH_MIPS_murlungs_430_Particles15

description:
Sample #	Group	OD 260/280	RNA, ug/ul	Actb Ct	Chip
1	PregPBS	2.0	0.63	13.8	a
2	PregPBS	2.0	0.647	13.3	j
3	PregPBS	2.1	0.612	13.4	l
4	PregPBS	2.0	0.575	13.8	m
6	PregTiO	2.1	0.585	14.3	n
8	PregTiO	2.1	0.458	13.8	o
9	NormPBS	2.0	0.627	13.3	p
11	NormPBS	2.0	0.714	13.4	b
12	NormPBS	2.1	0.462	13.8	c
13	NormTiO	2.0	0.572	15.6	d
14	NormTiO	2.1	0.598	13.1	e
15	NormTiO	2.1	0.682	13.6	f
16	NormTiO	2.1	0.654	13.6	g
17	PregTiO	2.1	0.586	13.7	h
18	PregTiO	2.0	0.833	12.8	i
20	NormPBS	2.0	0.804	12.5	k

hyb_protocol: Hybridization is carried out according the Affymetrix GeneChip® Manual. Twenty micrograms of IVT material is the nominal amount used on the GeneChip® arrays.  Affymetrix hybridization ovens are used to incubate the arrays at a constant temperature of 45oC overnight.

scan_protocol: Preparation of microarrays for scanning is carried out with Affymetrix appropriate wash protocols matched to the specific chip type on a Model 450 Fluidics station.  Affymetrix GeneChip Operating Software (GCOS) operating system controls the Fluidics station process. Scanning is carried out on a GeneChip® Scanner 3000 7G scanner with autoloader. The Affymetrix GCOS v1.3 operating system controls the Model 3000 7G scanner and data acquisition functions. GCOS maintains the mediated first level data analysis and desktop data management for the entire GeneChip System. Chip library files specific to each array and necessary for scan interpretation are stored on the computer workstation controlling the scanner and are updated regularly as necessary when updates are made available from Affymetrix. Collected research data is stored on the hard drive of the instrument computer, transferred to a mirrored storage disk and to  a raid 5 server operating on the Partners Healthcare network and backed up nightly via the Partners Healthcare Systems IT backup utility.  All systems are CFR21-11 and HIPPA compliant

source_name: Total lung RNA of pregnant mouse exposed to TiO2 particle insufflation

label_protocol:
For each experimental sample, RNA quality was assessed by RNA Nano LabChip analysis on an Agilent Bioanalyzer 2100. Concentrations may also be determined using a NanoDrop 1000 spectrophotometer. Under standard conditions processing of RNAs for GeneChip Analysis was in accordance with methods described in the Affymetrix GeneChip Expression Analysis Technical Manual, revision four, as subsequently detailed.   Synthesis of cDNA first and second strand is performed using the GeneChip Expression 3’-Amplification Reagents One-Cycle cDNA Synthesis Kit (P/N 900431).  Cleanup of the double stranded product is carried according to standard Affymetrix protocols using the Affymetrix GeneChip Cleanup Module (Affymetrix Catalog # 900371).
In vitro transcription (IVT) is performed using the GeneChip Expression Amplification Reagents kit- 30 reactions (P/N 900449) and is carried out according to the standard Affymetrix protocols and quantification of the IVT samples is carried out on a Bio-Tek UV Plate Reader.

extract_protocol: Qiagen RNeasy with on-column DNAse digestion and dual elution.

value: day 14

value: 50 ug/mouse of titanium dioxide particle suspension in PBS by intranasal insufflation


title: HSPH_MIPS_murlungs_430_Particles14


title: HSPH_MIPS_murlungs_430_Particles16

source_name: Total lung RNA of normal mouse exposed to PBS insufflation

value: non-pregnant


title: HSPH_MIPS_murlungs_430_Particles11


title: HSPH_MIPS_murlungs_430_Particles13


title: HSPH_MIPS_murlungs_430_Particles9


title: HSPH_MIPS_murlungs_430_Particles8


title: HSPH_MIPS_murlungs_430_Particles6

source_name: Total lung RNA of normal mouse exposed to TiO2 particle insufflation


title: HSPH_MIPS_murlungs_430_Particles10


title: HSPH_MIPS_murlungs_430_Particles3


title: brain, forebrain: Total RNA from primary neurons_le1

status: Public on Jun 27 2007

description: Primary neuronal cultures from the ventricular and subventricular zone of the medial ganglionic eminence (rostral part), from E15.5 WT embryos

source_name: brain, forebrain


title: brain, forebrain: Total RNA from neuronal progenitors +/_le1

description: Ventricular and subventricular zone of the medial ganglionic eminence (rostral part), from E15.5 WT embryos


title: met1-3_leaf_second-selfed generation_rep01

type: genomic

city: Genève

first: Jon

last: Reinders

state: Genève

address: 30 quai Ernest-Ansermet

department: Department of Plant Biology

country: Switzerland

institute: Universite de Geneve

description: Two replicate 3 µg genomic DNA samples of 2nd generation met1-3, 4th generation met1-3 and Col-0 were sheared by sonication and methylated DNA was immunoprecipitated, as previously described (Weber et al., 2005), and amplified following the chromatin immunoprecipitation assay protocol (Affymetrix).

data_processing: The .CHP files were generated with the Affymetrix GCOS software for preliminary analysis of the methylation values. The raw .CEL files were directly used for the methylation analysis. Using the gcRMA method, background adjustments were made and background-adjusted values from the six ATH1 datasets were quantile normalized using the Bioconductor package of R. Average signal intensities were determined in log2 scale per probe set. Contrast coefficient ratios for all pair-wise comparisons were calculated as follows: met1-3 2nd/Col-0, met1-3 4th/Col-0, and met1-3 4th/met1-3 2nd. Corrections for multiple comparisons at the 5% false discovery rate (FDR) were performed and significant differences were detected using Fisher’s test. For each probe set, three outcomes (significantly hypermethylated, no difference, and significantly hypomethylated) were possible per comparison, creating 27 possible methylation profiles analyzed at the 5% FDR level.

label: Two replicates per entry with 7.5 µg DNA were fragmented; end labeled, and hybridized on Affymetrix ATH1 arrays as recommended (Affymetrix).

molecule: genomic DNA

organism: Arabidopsis thaliana

source_name: leaf tissue (approx. 12th true leaf)

label_protocol:
Affymetrix Double standed DNA Labelling reaction.
Manufacturer's protocol, see manufacturer's web site

growth_protocol: Plants were grown in soil under short-day conditions (8 h light/16 h dark) at 22°C.

extract_protocol: Per entry, two biological replicates of leaf tissue (approx. 12th true leaf) from 9-12 plants were frozen in liquid nitrogen. DNA was CTAB extracted and isopropanol precipitated, RNase A and Proteinase K treated, re-extracted and ethanol precipitated.


title: HSPH_MIPS_murlungs_430_Particles2


title: Colon - 383410

status: Public on Jun 25 2007

first: Erin

last: Curley

address: 445 N. 5th Street

institute: IGC

description:
Quality metric = 28S to 18S: 1.7
Patient Age: 50-60
Gender: Male
Ethnic Background: African-American
Tobacco Use : Yes
Years of Tobacco Use: 11-15
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 13
Presenting Symptoms: Abdominal Pain
Presenting Symptoms: Bright red stools
Presenting Symptoms: Constipation
Screening studies performed?: No
Diagnosis made by: Colonoscopy
Pathological T: 3
Pathological N: 0
Pathological M: X
Pathological Stage: Unknown
Pathological Grade: 2
Primary Site: Colon
Histology: Mucinous Carcinoma

source_name: Colon


title: Col_ leaf_ wildtype_rep01

hyb_protocol: Manufacturer's protocol, see manufacturer's web site

tag: Columbia


title: Cervix Uteri - 383409

description:
Quality metric = 28S to 18S: 1.6
Patient Age: 50-60
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 36-40
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: Yes
Prior Therapy: Chemotherapy
Pathological T: 2b
Pathological N: 0
Pathological M: 0
Pathological Stage: 2B
Pathological Grade: 2
Pathological Staged During or Following Multimodality Therapy: Yes
Primary Site: Cervix Uteri
Histology: Squamous cell carcinoma, non-keratinizing

source_name: Cervix Uteri


title: Pelvic mass - 383398

description:
Quality metric = 28S to 18S: 1.3
Patient Age: 70-80
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: No
Prior Therapy: Chemotherapy
Prior Therapy: Radiation
Prior Therapy: Surgical
Pathological T: 3a
Pathological N: X
Pathological M: 1
Pathological Metastatic Sites: Other
Pathological Stage: 4B
Pathological Grade: 3
Primary Site: Endometrium
Histology: Metastatic Endometrioid carcinoma

source_name: Pelvic mass


title: HSPH_MIPS_murlungs_430_Particles4

source_name: Total lung RNA of normal mouse exposed to TiO2 particles insufflation


title: met1-3_leaf_second-selfed generation_rep02

scan_protocol: Manufacturer's protocol, see manufacturer's web site


title: Col_ leaf_ wildtype_rep02


title: brain, forebrain: Total RNA from primary neurons -/-_le1

description: Primary neuronal cultures from the ventricular and subventricular zone of the medial ganglionic eminence (rostral part), from E15.5 Dlx1/2 mutant embryos


title: Uterus - 383397

description:
Quality metric = 28S to 18S: 1.9
Patient Age: 60-70
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 21
Pathological T: 1a
Pathological N: 0
Pathological M: 0
Pathological Stage: 1A
Pathological Grade: 2
Primary Site: Endometrium
Histology: Endometrioid carcinoma

source_name: Uterus


title: Kidney - 388910

description:
Quality metric = 28S to 18S: 1.8
Patient Age: 50-60
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 6-10
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: Yes
Family History of Cancer?: No
Pathological T: 1b
Pathological N: 0
Pathological M: 0
Pathological Stage: 1
Pathological Grade: 3
Primary Site: Kidney
Histology: Conventional (clear cell) renal carcinoma

source_name: Kidney


title: brain, forebrain: Total RNA from neuronal progenitors -/-_le1

description: Ventricular and subventricular zone of the medial ganglionic eminence (rostral part), from E15.5 Dlx1/2 mutant embryos


title: HSPH_MIPS_murlungs_430_Particles7


title: met1-3_leaf_fourth-selfed generation_rep02


title: HSPH_MIPS_murlungs_430_Particles1


title: met1-3_leaf_fourth-selfed generation_rep01


title: brain, forebrain: MGE -/- (2)_e1_le1


title: Uterus - 383401

description:
Quality metric = 28S to 18S: 1.7
Patient Age: 60-70
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: No
Days from Patient Diagnosis to Excision: 54
Pathological T: 1c
Pathological N: 1
Pathological M: 0
Pathological Stage: 3C
Pathological Grade: 3
Primary Site: Endometrium
Histology: Malignant mixed Mullerian tumor


title: HSPH_MIPS_murlungs_430_Particles5


title: Omentum - 371446

description:
Quality metric = 28S to 18S: 1.5
Patient Age: 60-70
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 31-35
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: Yes
Clinical Question: Stage
Clinical Value: No AJCC Scheme for unknown primary
Primary Site: Unknown
Clinical Question: Histology
Clinical Value: Metastatic Mucinous adenocarcinoma

source_name: Omentum


title: placebo 9d, biological rep1

description: Gene expression data from ventral prostate of wild type FVB mice and FVB-AKT1 mice treated with placebo or rad001 for 12h, 2d, 6d, 9d, and 15d

source_name: ventral prostate of transgenic FVB mice

treatment_protocol: placebo for 9d


title: Cervix Uteri - 371439

description:
Quality metric = 28S to 18S: 1.1
Patient Age: 50-60
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 14
Have you ever been diagnosed as having HPV on your PAP smear?: No
Clinical T: 2b
Clinical N: 0
Clinical M: 1
Clinical Metastatic Sites: Pulmonary
Clinical Stage: 4B
Clinical Grade: 3
Primary Site: Cervix Uteri
Histology: Small cell carcinoma, NOS


title: Lung - 371434

description:
Quality metric = 28S to 18S: 1.4
Patient Age: 80-90
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 30
Presenting Symptoms: Persistent Cough
Pathological T: 2
Pathological N: 0
Pathological M: 0
Pathological Stage: 1B
Pathological Grade: 2
Primary Site: Lung
Histology: Mucinous bronchioloalveolar carcinoma

source_name: Lung


title: Breast - 371441

description:
Quality metric = 28S to 18S: 1.6
Patient Age: 70-80
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 38
Mammogram: Yes
Number of years in which a mammogram was obtained?: 21-25
Oophorectomy?: No
Hormonal therapy (# of Years)?: 0-5
Pathological T: 1c
Pathological N: 1a
Pathological M: 0
Pathological Stage: 2A
Pathological Grade: 2
Pathological ER: Positive
Pathological PR: Positive
Pathological HER/2 Neu: Negative
Primary Site: Breast
Histology: Lobular Carcinoma

source_name: Breast


title: Urinary bladder - 371445

description:
Quality metric = 28S to 18S: 1.7
Patient Age: 50-60
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: No
Pathological T: 3a
Pathological N: 1
Pathological M: 0
Pathological Stage: 4
Pathological Grade: 3
Primary Site: Urinary Bladder
Histology: Urothelial (transitional cell) carcinoma

source_name: Urinary bladder


title: Kidney - 371436

description:
Quality metric = 28S to 18S: 1.2
Patient Age: 40-50
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 26-30
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: Yes
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 54
Pathological T: 1a
Pathological N: 0
Pathological M: 0
Pathological Stage: 1
Pathological Grade: X
Pathological Multiple Tumors: Yes
Primary Site: Kidney
Histology: Papillary renal cell carcinoma


title: Rectum - 371435

description:
Quality metric = 28S to 18S: 1.5
Patient Age: 60-70
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 31-35
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: Yes
Family History of Cancer?: No
Days from Patient Diagnosis to Excision: 25
Presenting Symptoms: Constipation
Presenting Symptoms: Diarrhea
Diagnosis made by: Colonoscopy
Pathological T: 2
Pathological N: 0
Pathological M: 0
Pathological Stage: 1
Pathological Grade: 2
Pathological Dukes Stage: A
Primary Site: Rectum
Histology: Mucinous Carcinoma

source_name: Rectum


title: Uterus - 371430

description:
Quality metric = 28S to 18S: 1.3
Patient Age: 50-60
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: Yes
Family History of Cancer?: No
Pathological T: 2b
Pathological N: 0
Pathological M: 0
Pathological Stage: 2B
Pathological Grade: 1
Primary Site: Endometrium
Histology: Endometrioid carcinoma


title: Kidney - 371438

description:
Quality metric = 28S to 18S: 1.5
Patient Age: 70-80
Gender: Male
Ethnic Background: African-American
Tobacco Use : Yes
Years of Tobacco Use: 36-40
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: No
Days from Patient Diagnosis to Excision: 83
Clinical T: 1a
Clinical N: 0
Clinical M: 0
Clinical Stage: 1
Clinical Grade: 2
Primary Site: Kidney
Histology: Conventional (clear cell) renal carcinoma


title: Kidney - 362607

description:
Quality metric = 28S to 18S: 1.1
Patient Age: 70-80
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 11-15
Type of Tobacco Use: Cigarettes
Type of Tobacco Use: Cigars
Alcohol Consumption?: Yes
Family History of Cancer?: No
Days from Patient Diagnosis to Excision: 42
Pathological T: 2
Pathological N: 0
Pathological M: 0
Pathological Stage: 2
Pathological Grade: 3
Primary Site: Kidney
Histology: Chromophobe renal carcinoma


title: Liver - 362575

description:
Quality metric = 28S to 18S: 1.6
Patient Age: 70-80
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 16-20
Type of Tobacco Use: Chewing Tobacco
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 54
Presenting Symptoms: Abdominal Pain
Presenting Symptoms: Constipation
Diagnosis made by: Colonoscopy
Pathological T: 4
Pathological N: 1
Pathological M: 1
Pathological Metastatic Sites: Hepatic
Pathological Stage: 4
Pathological Grade: 2
Primary Site: Colon
Histology: Metastatic Adenocarcinoma

source_name: Liver


title: Lung - 362601

description:
Quality metric = 28S to 18S: 1.5
Patient Age: 70-80
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 61-65
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: Yes
Presenting Symptoms: SOB
Workplace or household smokers?: No
Pathological T: 1
Pathological N: 0
Pathological M: 0
Pathological Stage: 1A
Pathological Grade: 2
Primary Site: Lung
Histology: Large cell carcinoma


title: Ovary - 362603

description:
Quality metric = 28S to 18S: 1.3
Patient Age: 60-70
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 41-45
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 30
Presenting Symptoms: Abdominal pain
Presenting Symptoms: Bloating
Pathological T: 3c
Pathological N: 1
Pathological M: 0
Pathological Stage: 3C
Pathological Grade: 3
Primary Site: Ovary
Histology: Papillary serous cystadenocarcinoma

source_name: Ovary


title: Uterus - 348069

description:
Quality metric = 28S to 18S: 1.4
Patient Age: 60-70
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: No
Days from Patient Diagnosis to Excision: 7
Clinical T: 1c
Clinical N: 0
Clinical M: 0
Clinical Stage: 1C
Clinical Grade: 2
Primary Site: Endometrium
Histology: Endometrioid carcinoma


title: Uterus - 362581

description:
Quality metric = 28S to 18S: 1.2
Patient Age: 50-60
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 36-40
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 22
Pathological Question: Stage
Pathological Value: No AJCC scheme for this site and histology
Primary Site: Myometrium
Pathological Question: Histology
Pathological Value: Leiomyosarcoma


title: Ovary - 371447

description:
Quality metric = 28S to 18S: 1.6
Patient Age: 50-60
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 0-5
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: No
Family History of Cancer?: Yes
Presenting Symptoms: Abdominal pain
Pathological T: 3c
Pathological N: 1
Pathological M: 0
Pathological Stage: 3C
Pathological Grade: 3
Primary Site: Ovary
Histology: Papillary Serous Adenocarcinoma


title: Colon - 362605

description:
Quality metric = 28S to 18S: 1.7
Patient Age: 90-100
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: No
Days from Patient Diagnosis to Excision: 45
Presenting Symptoms: Diarrhea
Presenting Symptoms: Nausea
Diagnosis made by: Colonoscopy
Pathological T: 3
Pathological N: 0
Pathological M: 0
Pathological Stage: 2A
Pathological Grade: 3
Pathological Dukes Stage: B
Primary Site: Colon
Histology: Adenocarcinoma


title: Rectosigmoid - 362602

description:
Quality metric = 28S to 18S: 1.3
Patient Age: 70-80
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 0-5
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: Yes
Family History of Cancer?: No
Days from Patient Diagnosis to Excision: 12
Presenting Symptoms: Bright red stools
Screening studies performed?: No
Diagnosis made by: Colonoscopy
Pathological T: 3
Pathological N: 2
Pathological M: 0
Pathological Stage: 3C
Pathological Grade: 2
Pathological Dukes Stage: C
Primary Site: Rectosigmoid
Histology: Adenocarcinoma

source_name: Rectosigmoid


title: Breast - 366607

description:
Quality metric = 28S to 18S: 1.5
Patient Age: 50-60
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: No
Days from Patient Diagnosis to Excision: 124
Prior Therapy: Chemotherapy
Mammogram: Yes
Number of years in which a mammogram was obtained?: 16-20
Oral contraceptives?: Yes
Number of years of use? (Oral contraceptives): 0-5
Oophorectomy?: No
Fibrocystic disease?: No
Mammogram calcifications?: No
Pathological T: 2
Pathological N: 2a
Pathological M: 0
Pathological Stage: 3A
Pathological Grade: 2
Pathological Stage During or Following Multimodality Therapy: Yes
Pathological ER: Positive
Pathological PR: Positive
Pathological HER/2 Neu: Negative
Primary Site: Breast
Histology: Ductal Carcinoma


title: Thyroid - 348067

description:
Quality metric = 28S to 18S: 1.3
Patient Age: 50-60
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 14
Pathological T: 1
Pathological N: 1a
Pathological M: 0
Pathological Stage: 3
Primary Site: Thyroid
Histology: Papillary adenocarcinoma

source_name: Thyroid


title: Kidney - 348070

description:
Quality metric = 28S to 18S: 1.0
Patient Age: 40-50
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 8
Clinical T: 2
Clinical N: 0
Clinical M: 0
Clinical Stage: 2
Clinical Grade: 3
Primary Site: Kidney
Histology: Conventional (clear cell) renal carcinoma


title: Unspecified soft tissue from abdomen or pelvis - 362571

description:
Quality metric = 28S to 18S: 1.6
Patient Age: 70-80
Gender: Female
Ethnic Background: Caucasian
Tobacco Use : No
Alcohol Consumption?: No
Family History of Cancer?: No
Prior Therapy: Chemotherapy
Prior Therapy: Surgical
Relapse Since Primary Treatment: Yes
Number of Years Until Relapse: 0-5
Retreatment T: 3c
Retreatment N: X
Retreatment M: 0
Retreatment Stage: 3C
Retreatment Grade: X
Primary Site: Ovary
Histology: Metastatic Papillary Serous Adenocarcinoma


title: Prostate - 362600

description:
Quality metric = 28S to 18S: 1.3
Patient Age: 70-80
Gender: Male
Ethnic Background: Caucasian
Tobacco Use : Yes
Years of Tobacco Use: 31-35
Type of Tobacco Use: Cigarettes
Alcohol Consumption?: Yes
Family History of Cancer?: Yes
Days from Patient Diagnosis to Excision: 21
Presenting Symptoms: Hesitancy
Presenting Symptoms: Nocturia
Presenting Symptoms: Urgency
PSA: Elevated
# of years PSA Tested?: 0-5
Cancer discovered by digital exam?: No
Current status of disease: Under Therapy
Pathological T: 4
Pathological N: X
Pathological M: 0
Pathological Stage: 4
Pathological Grade: 3
Pathological Gleason Score: 7
Primary Site: Prostate
Histology: Adenocarcinoma, NOS

source_name: Prostate